Telix Pharmaceuticals Limited American Depositary Shares’ (TLX) “Outperform” Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) in a research note released on Wednesday,RTT News reports. William Blair also issued estimates for Telix Pharmaceuticals Limited American Depositary Shares’ FY2025 earnings at $0.82 EPS, FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.44 EPS.

Separately, UBS Group lifted their price target on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, January 27th.

Telix Pharmaceuticals Limited American Depositary Shares Stock Up 1.8 %

Shares of NASDAQ TLX opened at $17.30 on Wednesday. The business’s 50-day simple moving average is $17.47. Telix Pharmaceuticals Limited American Depositary Shares has a 1 year low of $14.01 and a 1 year high of $30.36.

Telix Pharmaceuticals Limited American Depositary Shares Company Profile

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.